Zacks: Atossa Genetics Inc (ATOS) Receives Average Rating of “Strong Buy” from Brokerages

Shares of Atossa Genetics Inc (NASDAQ:ATOS) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Analysts have set a 12-month consensus price objective of $9.00 for the company, according to Zacks. Zacks has also given Atossa Genetics an industry rank of 150 out of 255 based on the ratings given to its competitors.

A number of equities research analysts recently weighed in on the company. Maxim Group reaffirmed a “buy” rating and set a $9.00 price target on shares of Atossa Genetics in a report on Tuesday, March 26th. ValuEngine cut Atossa Genetics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th.

ATOS stock traded down $0.06 during midday trading on Friday, reaching $3.01. 100 shares of the company’s stock traded hands, compared to its average volume of 2,960,015. Atossa Genetics has a 1-year low of $0.80 and a 1-year high of $7.39. The stock has a market capitalization of $27.71 million, a price-to-earnings ratio of -0.55 and a beta of 3.79.

An institutional investor recently bought a new position in Atossa Genetics stock. Barclays PLC purchased a new position in shares of Atossa Genetics Inc (NASDAQ:ATOS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,384 shares of the company’s stock, valued at approximately $33,000. Barclays PLC owned about 0.57% of Atossa Genetics as of its most recent SEC filing. Institutional investors own 13.87% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Recommended Story: Insider Trading – What You Need to Know

Get a free copy of the Zacks research report on Atossa Genetics (ATOS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.